25 August 2021 | News
Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins
Image Credit: Shutterstock
Fusion Antibodies, a specialist in pre-clinical antibody discovery, engineering, and supply for both therapeutic drug and diagnostic applications, has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE group company; a leading provider of products and services to the drug discovery industry.
The collaboration between Fusion Antibodies and Eurofins Discovery will last for an initial two-year period and is a commitment to provide world-class scientific expertise, next-generation technology, and guidance to accelerate the delivery of the best possible antibody against a broad range of targets and therapeutic areas into the clinic.
Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that together they can provide a complete workflow solution for busy researchers. This includes Fusion Antibodies services for antibody generation, characterisation, sequencing, engineering and expression, and Eurofins Discovery’s in vivo and in vitro services, such as efficacy models, bioanalytical services, biomarker development, phenotypic assays and safety assessment.
Commenting on the partnership, Dr Richard Jones, CEO, Fusion Antibodies, said, "This partnership is a natural fit with Fusion’s mission to enable pharmaceutical and diagnostic companies to develop innovative products in the most efficient and cost-effective way.”
Dr Julie Gormley, Business Development Director of Fusion Antibodies, said: “This partnership brings together two world leaders in their respective fields and will enable scientists to focus on their research while our services ensure efficient and robust results. I look forward to working closely with colleagues at Eurofins Discovery throughout 2021 and beyond.”